BioSpace News Archive

Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced enrollment of the first patients in a multicenter, Phase 2 trial to evaluate the safety of fostamatinib, Rigel’s oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of hospitalized COVID-19 patients.

Swedish Orphan Biovitrum AB (publ) (Sobi™) (STO:SOBI) today announced topline results from its phase 3 study of avatrombopag, an oral thrombopoietin (TPO) receptor agonist, in solid tumour cancer patients with chemotherapy-induced thrombocytopenia (CIT).

AIVITA Biomedical, Inc., a private biotechnology company developing personalized vaccines for the treatment of cancer and COVID-19, announced today the publication of the peer-reviewed manuscript, “Retina organoid transplants develop photoreceptors and improve visual function in RCS rats with RPE dysfunction,”

Connectyx Technologies Holdings Group, Inc. (OTC: CTYX) (“Connectyx” or the “Company”), a development-stage biomedical company focusing on novel treatments for rare diseases, announced today the Company has signed a definitive agreement with Mid-Atlantic BioTherapeutics, Inc. (MABT) to acquire worldwide rights for the development of IMT504, a novel, patented immunotherapy, to treat symptomatic rabies.

Retrophin, Inc. (NASDAQ: RTRX) today announced that it will present new data from a post-hoc analysis examining the proportion of patients with focal segmental glomerulosclerosis (FSGS) that achieved complete remission of proteinuria in the Phase 2 DUET Study, at the American Society of Nephrology (ASN) Kidney Week 2020 Reimagined. The Company and its collaborators will also feature encore presentations of preclinical data supporting the potential f

Adamas Pharmaceuticals, Inc. announced that the compensation committee of the company’s board of directors granted four new employees the option to purchase an aggregate of 161,000 shares of the company’s common stock, at a per share exercise price of $4.45, the closing trading price on October 7, and restricted stock units to acquire 80,500 shares of the company’s common stock.

Dicerna Pharmaceuticals, Inc. (Nasdaq: DRNA) (the “Company” or “Dicerna”), a leading developer of investigational ribonucleic acid interference (RNAi) therapeutics, today announced that clinical data on nedosiran, an investigational candidate for the treatment of primary hyperoxaluria (PH), will be presented during the American Society of Nephrology (ASN) Kidney Week taking place Oct. 22-25, 2020. In addition, a commer

Scientific Industries, Inc. (OTCQB:SCND) - For the year ended June 30, 2020, the Company reported a net loss of $703,300, or ($.46) per basic share, compared to net income of $645,600, or $.43 per basic share for the year ended June 30, 2019 on revenues of $8,570,300, a decrease of $1,629,500 (16%) compared to $10,199,800 for the year ended June 30, 2019.

ADC Therapeutics SA (NYSE: ADCT), a late clinical-stage oncology-focused biotechnology company pioneering the development and commercialization of highly potent and targeted antibody drug conjugates for patients with hematological malignancies and solid tumors, announced today the underwriters in its recent upsized public offering of 6,000,000 common shares, which closed on September 28, 2020, have exercised in full

National Health Investors, Inc. (NYSE:NHI) announced details for the release of its results for the third quarter ended September 30, 2020.